Literature DB >> 19860687

Role of chemokines and their receptors in cancer.

Roeliene C Kruizinga1, Jovanka Bestebroer, Paul Berghuis, Carla J C de Haas, Thera P Links, Elisabeth G E de Vries, Annemiek M E Walenkamp.   

Abstract

Metastases are the cause of 90% of human cancer deaths. The current treatment of cancer with chemo,- and/or radiotherapy is based on cell death by DNA damage neglecting the fact that cancer cell invasion into surrounding tissues and metastasizing are fundamental features of neoplasms and the major reason for treatment failure. Metastasis is the result of several sequential steps and represents a highly organized, non-random, and organ-selective process. A number of in vitro and in vivo models show that tumor cells use chemokine-mediated mechanisms during this metastasizing process, comparable to those observed in the regulation of leukocyte trafficking. Furthermore, chemokines modulate tumor behavior such as the regulation of tumor-associated angiogenesis, activation of host tumor-specific immunological responses, and direct stimulation of tumor cell proliferation in an autocrine fashion. These findings may lead to new drugs that target chemokines or their receptors and will likely be of great additional value for treatment of cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860687     DOI: 10.2174/138161209789105081

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  23 in total

1.  Transforming growth factor β in cancer: Janus, the two-faced god.

Authors:  David Salomon
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

Review 2.  CXC chemokines in cancer angiogenesis and metastases.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 3.  Chemokines and their receptors in esophageal cancer--the systematic review and future perspectives.

Authors:  Marta Łukaszewicz-Zając; Barbara Mroczko; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2015-07-01

Review 4.  CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.

Authors:  Xueqing Sun; Guangcun Cheng; Mingang Hao; Jianghua Zheng; Xiaoming Zhou; Jian Zhang; Russell S Taichman; Kenneth J Pienta; Jianhua Wang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

5.  Apigenin suppresses migration and invasion of transformed cells through down-regulation of C-X-C chemokine receptor 4 expression.

Authors:  Lei Wang; Lisha Kuang; John Andrew Hitron; Young-Ok Son; Xin Wang; Amit Budhraja; Jeong-Chae Lee; Poyil Pratheeshkumar; Gang Chen; Zhuo Zhang; Jia Luo; Xianglin Shi
Journal:  Toxicol Appl Pharmacol       Date:  2013-06-04       Impact factor: 4.219

6.  The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.

Authors:  Israa G Akram; Rania Georges; Thomas Hielscher; Hassan Adwan; Martin R Berger
Journal:  Tumour Biol       Date:  2015-09-18

7.  Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma.

Authors:  K S Im; A J Graef; M Breen; K Lindblad-Toh; J F Modiano; J-H Kim
Journal:  Vet Comp Oncol       Date:  2015-09-03       Impact factor: 2.613

8.  CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling.

Authors:  Amr A Al-haidari; Ingvar Syk; Karin Jirström; Henrik Thorlacius
Journal:  Int J Colorectal Dis       Date:  2013-05-07       Impact factor: 2.571

9.  Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression.

Authors:  Xiu-Jie Sheng; Ying-Qun Zhou; Qing-Yuan Song; Dong-Mei Zhou; Qi-Cai Liu
Journal:  Oncol Rep       Date:  2011-12-19       Impact factor: 3.906

10.  Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines.

Authors:  Feng Ying Wu; Jiang Fan; Liang Tang; Yin Min Zhao; Cai Cun Zhou
Journal:  Oncol Lett       Date:  2013-05-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.